Promethera has developed a series of research and development as well as collaborative partnerships. These agreements are signed with both academic and industrial partners, designed to help Promethera broaden and accelerate its clinical development.
(a) a licence agreement for HepaStem and H2Stem to develop and commercialize these platforms in Promethera’s main indications in NASH and ACLF in Korea and
(b) a supply agreement to provide Heparesc for LifeLiver’s proprietary bioartificial liver (BAL) system.
Promethera and LifeLiver will collaborate on the clinical development of Promethera's and LifeLiver’s product applications. Initially, LifeLiver will combine Promethera's human mature hepatocytes liver cell suspension, Heparesc, with its proprietary bioartificial liver (BAL) system for the ex vivo treatment of patients with severe liver diseases such as Acute Liver Failure. The therapeutic goal of this approach would be to “humanize” the BAL bioreactor and to boost supply of hepatocytes. Future directions of this strategic alliance will involve other indications currently clinically investigated by Promethera such as urea cycle disorders and will include the HepaStem and H2Stem technologies.
In October 2017 Promethera and Shibuya announced a strategic collaboration to establish a high-throughput, commercial-scale and clinical-grade cell therapy and regenerative medicine manufacturing platform.
For Promethera, the collaboration will act as a cornerstone to optimize and expand the manufacturing capabilities for its current and future portfolio of liver-derived cell therapies to treat Non-Alcoholic Steatohepatitis (NASH), acute-on-chronic liver-failure (ACLF) and other indications.
For Shibuya, the collaboration represents a significant step towards bringing the company’s expertise to the European market and becoming a global leader in the manufacturing of regenerative medicine products.
Beginning of 2019 Promethera welcomed Itochu Corporation, one of the biggest Japan- based business conglomerate with global presence and networks, as a strategic investor.
Beyond the investment, ITOCHU intends to support Promethera to advance Promethera’s product and business development strategy in Asia. The scope of the relationship includes R&D support for Promethera’s HepaStem development program in Acute on Chronic Liver Failure (ACLF), Non-Alcoholic Steatohepatitis (NASH) and Urea Cycle Disorder (UCD) in selected Asian markets.
Promethera is collaborating with PALL to develop innovative manufacturing processes.
Université Catholique de Louvain and the Pediatric Hepatology and Cell Therapy Laboratory
Promethera Biosciences has an ongoing collaboration agreement with Université Catholique de Louvain and the Pediatric Hepatology and Cell Therapy Laboratory.
ULB (Université Libre de Bruxelles)
Promethera Biosciences has an agreement for its histology studies and bio-marker research with the CMMI department of the ULB.
University College of London
Early 2015 Promethera entered into a collaborative partnership with University College of London. The partnership includes the possibility of developing 3D engineered tissues by combining human liver biological scaffolds and human liver-derived stem cells.
Promethera Biosciences received funding from:
- The Walloon Region, Belgium (DGO6) and the EU have granted conditional loans and subsidies for Promethera to develop its cell therapy products and conduct clinical studies for targeted indications for a total amount of 22.78 million euros.
- The amount granted in RCA’s is 20.2 million euros
- 1.8 million euros in subsidies
- 0.78 million euros from FEDER funds (European Fund for Economic and Regional Development)
- L'agence Wallonne de l'Exportation (AWEX), Belgium supports the international development of Promethera Biosciences.
In 2011, Promethera entered into a collaboration with the CER groupe in order to conduct in-vivo pre-clinical studies for its cell-therapy products. In addition, in January 2016 both companies started to collaborate on a new CWALity project, partially funded by the Walloon region.